Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26121631 | 0.92 | HDAC6 (0.48) | HDAC6HDAC1 | |
| SCHEMBL30574346 | 0.92 | HDAC6 (0.48) | HDAC6HDAC1 | |
| SCHEMBL26530409 | 0.83 | KDM4E (0.46) | HDAC6HDAC1KDM4ENPC1ALDH1A1 | |
| SCHEMBL26530504 | 0.81 | HDAC6 (0.43) | HDAC6HDAC1 | |
| SCHEMBL26530515 | 0.81 | HDAC6 (0.43) | HDAC6HDAC1 | |
| SCHEMBL26530517 | 0.79 | HDAC6 (0.46) | HDAC6HDAC1 | |
| SCHEMBL26529961 | 0.79 | HDAC6 (0.52) | HDAC6HDAC1 | |
| SCHEMBL26531224 | 0.78 | HDAC6 (0.48) | HDAC6HDAC1 | |
| SCHEMBL26530549 | 0.78 | HDAC6 (0.41) | HDAC6HDAC1KDM4ENPC1ALDH1A1 | |
| SCHEMBL26530511 | 0.77 | HDAC6 (0.43) | HDAC6HDAC1KDM4ENPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC11 | HDAC6 1/4885HDAC1 2/4885KDM4E 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.